{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:34:47Z","timestamp":1777890887522,"version":"3.51.4"},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303134"],"award-info":[{"award-number":["82303134"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303547"],"award-info":[{"award-number":["82303547"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Existing evidence indicates that germline BRCA mutation (gBRCA\u2010m) may increase chemotherapy sensitivity and toxicity. However, its role in chemotherapy\u2010induced myelosuppression (CIM) remains unclear. We conducted this study to investigate the influence of gBRCA\u2010m on CIM incidence and severity in patients with epithelial ovarian carcinoma (EOC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with EOC treated at the First Affiliated Hospital of Nanjing Medical University from January 2018 to August 2023 were classified into two groups: gBRCA\u2010m and gBRCA wild\u2010type. Chemotherapy regimen and myelosuppression data were retrospectively reviewed. Multivariate analysis assessed the association between gBRCA\u2010m and CIM incidence and severity in patients with EOC receiving first\u2010line chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixty six (27%) of 242 included patients were gBRCA\u2010m carriers. The median times to myelosuppression onset and the most severe occurrence were significantly shorter for patients with gBRCA\u2010m (6.0 vs. 27.0\u2009days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; 73.5 vs. 121.0\u2009days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Patients with gBRCA\u2010m had a greater likelihood of Grade IV (GIV) myelosuppression at onset (aOR\u2009=\u20095.585, 95% CI\u2009=\u20091.621\u201319.241). During the most severe myelosuppression, patients with gBRCA\u2010m experienced more pronounced decreases in white blood cells (1.83\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      vs. 2.33*10\n                      <jats:sup>9<\/jats:sup>\n                      \u2009cells\/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), neutrophils (0.73\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      vs. 1.08\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \u2009cells\/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), haemoglobin levels (90.41 vs. 94.14\u2009g\/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017) and platelets (81.62\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      vs. 97.63\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \u2009cells\/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) and were more prone to febrile GIV myelosuppression (aOR\u2009=\u20092.882, 95% CI\u2009=\u20091.071\u20137.754). The incidences of chemotherapy dose reduction (aOR\u2009=\u20094.322, 95% CI\u2009=\u20092.048\u20139.124) and delay (aOR\u2009=\u20096.045, 95% CI\u2009=\u20092.266\u201316.126) were significantly greater in patients with gBRCA\u2010m. An analysis across all chemotherapy cycles indicated that patients with gBRCA\u2010m had greater risks of GIII (aOR\u2009=\u20092.356, 95% CI\u2009=\u20091.770\u20133.137), GIV (aOR\u2009=\u20092.324, 95% CI\u2009=\u20091.685\u20133.207) myelosuppression and GIV myelosuppression with fever (aOR\u2009=\u20092.097, 95% CI\u2009=\u20091.077\u20134.083), as well as a greater incidence of chemotherapy dose reduction (aOR\u2009=\u20092.606, 95% CI\u2009=\u20091.785\u20133.805) and delay (aOR\u2009=\u20094.118, 95% CI\u2009=\u20092.213\u20137.663).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>EOC patients with gBRCA\u2010m experienced earlier and more severe CIM, highlighting the need for careful monitoring and tailored management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71724","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T03:54:39Z","timestamp":1773374079000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemotherapy\u2010Induced Myelosuppression in Patients With\n                    <scp>gBRCA<\/scp>\n                    \u2010m Epithelial Ovarian Cancer: A Retrospective Study"],"prefix":"10.1002","volume":"15","author":[{"given":"Hongtao","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Gynaecology The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital  Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianglin","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Gynaecology The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital  Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Gynaecology The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital  Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoyi","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine Women and Children's Hospital of Ningbo University  Zhejiang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gynaecology The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital  Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gynaecology The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital  Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gynaecology The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital  Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmei","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Gynaecology The First Affiliated Hospital of Zhengzhou University  Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gynaecology The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital  Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Gynaecology The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital  Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shulin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Gynaecology The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital  Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8154-8670","authenticated-orcid":false,"given":"Chengyan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Gynaecology The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital  Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Gynaecology The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital  Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3134-4853","authenticated-orcid":false,"given":"Wenjun","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Gynaecology The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital  Nanjing Jiangsu China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00881-3"},{"issue":"4","key":"e_1_2_13_4_1","first-page":"284","article-title":"Ovarian Cancer Statistics, 2018","volume":"68","author":"Orre L. A.","year":"2018","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21559"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601043340101"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac074"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155810"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202302244"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11102547"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2955"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2287"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.12.007"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100238"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1246"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000001065"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.807748"},{"key":"e_1_2_13_18_1","unstructured":"National Cancer Institute \u201cCommon Terminology Criteria for Adverse Events (CTCAE) v5.0 \u201d(2017)."},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0007"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C000276200"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3777-0"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2471"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/igc.0000000000001144"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-006-0034-9"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-023-00331-6"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000354834"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010024\u201004670\u20108"},{"issue":"5","key":"e_1_2_13_29_1","first-page":"381","article-title":"Treatment Related Toxicity in BRCA1\u2010Associated Epithelial Ovarian Cancer \u2010 Is DNA Repairing Impairment Associated With More Adverse Events?","volume":"20","author":"Badora\u2010Rybicka A.","year":"2016","journal-title":"Contemporary Oncology (Poznan)"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.04.009"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01900"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02175-9"},{"issue":"2","key":"e_1_2_13_34_1","first-page":"100","article-title":"Update on PARP Inhibitors for the Treatment of Ovarian Cancer","volume":"23","author":"Liu J.","year":"2025","journal-title":"Clinical Advances in Hematology & Oncology"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.783"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.05.063"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3335"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI189511"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0257"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71724","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71724","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:48:27Z","timestamp":1777614507000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/cam4.71724"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71724","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-05-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71724"}}